Haemophilus influenzae type b vaccine

Many factors have to be considered when developing combination vaccines. First the selected components need to be given on a similar schedule and all components should already be licensed in the United States. The excipients contained in the individual vaccines may interfere with another component when combined, altering a component s immunogenicity. Finally, the immunogenicity of the combination must be similar (within 10%) to the immune response when the components are administered separately. This has been problematic with combinations containing Haemophilus influenza type b vaccine, for which the immune response has been significantly blunted in some combinations.13... [Pg.1247]

Karvonen M, Cepaitis Z, Tuomilehto J. Association between type 1 diabetes and Haemophilus influenzae type b vaccination birth cohort study. BMJ 1999 318(7192) 1169-72. [Pg.670]

Bewley KM, Schwab JG, BaUanco GA, Daum RS. Interchangeabihty of Haemophilus influenzae type b vaccines in the primary series evaluation of a two-dose mixed regimen. Pediatrics 1996 98(5) 898-904. [Pg.1572]

Bhaskaram MDP, Arun Jyothia S, Viswes-wara Raoa DK, Newton S, Owusu-Agyei S, Ampofo W, Zandoh C, Adjuik M, Adjei G, Tchum S, Filteau S, Kirkwood BR. Vitamin A supplementation enhances infants immune responses to hepatitis B vaccine but does not affect responses to Haemophilus influenzae type b vaccine. J Nutr 2007 137(5) 1272-7. [Pg.702]

There are a number of practical problems involved with using polysaccharides as vaccines as there are frequently too many different chemotypes for it to be practicable to prepare a vaccine. In some cases a limited number of serotypes are the dominant cause of infection and it may then be possible to produce vaccines. A major problem is the poor immune response elicited by polysaccharide antigens, which may in some cases be improved by chemical modification. This is (fie case for vaccines for Haemophilus influenzae type b (a causative agent of meningitis), where the antigenicity of the polysaccharide can be increased by coupling to proteins. [Pg.228]

Haemophilus influenzae type b conjugate and hepatitis B vaccine he -maw-fil-us in-flu-en -zah kon-jew -gate hep -ah-tie -tus bee-vak -seen Lyme disease vaccine (recombinant OspA) lime-vak -seen... [Pg.569]

Haemophilus influenzae type b (Hib) conjugate vaccine. Three Hib conjugate vaccines are licensed for infant use. If PRP-OMP (PedvaxHIB or ComVax) is administered at ages 2 and 4 months, a dose at age 6 months is not required. DTaP/Hib combination products should not be used for primary immunization in infants at ages 2, 4 or 6 months, but can be used as boosters following any Hib vaccine. [Pg.575]

Parisi, L. and von Hunolstein, C., Determination of the molecular size distribution of Haemophilus influenzae type b-tetanus toxoid conjugate vaccines by size-exclusion chromatography, /. Chromatogr. A, 847, 209, 1999. [Pg.382]

There are several combination vaccines available in the United States. One of the most popular pediatric combinations is Pediarix a combination of diphtheria and tetanus toxoids, acellular pertussis, inactivated poliovirus, and hepatitis B vaccines. ComVax is a combination of Haemophilus influenzae type b and hepatitis B vaccines. The most recent combination is ProQuad which contains measles, mumps, rubella, and varicella vaccines. The only combination available for adults is Twinrix which has hepatitis A and hepatitis B vaccines. [Pg.1247]

Following hematopoietic stem cell transplantation the patient will need virtually all routine vaccines to be administered again however, the patient will not be able to mount an adequate response for 6 to 12 months post-transplant. Diphtheria, tetanus, acellular pertussis, Haemophilus influenzae type b, hepatitis B, pneumococcal, and inactivated poliovirus should be given at 12,14, and 24 months post-hematopoietic stem cell transplantation. Inactivated influenza vaccine should be given yearly, starting 6 months after transplant. Measles, mumps and rubella can be given 2 years after transplant and varicella vaccine is contraindicated.16... [Pg.1249]

Comvax Haemophilus b conjugate and hepatitis b vaccine Merck Vaccination against invasive Haemophilus influenzae type b (Hib) and hepatitis B... [Pg.694]

V. Verez-Bencomo, V. Femandez-Santana, E. Hardy, M. E. Toledo, M. C. Rodriguez, L. Heynngnezz, A. Rodriguez, A. Baly, L. Herrera, M. Izquierdo, A. Villar, Y. Valdes, et al., A synthetic conjugate polysaccharide vaccine against Haemophilus influenzae type b, Science, 305 (2004) 522-525. [Pg.359]

Anderson, P.W., Pichichero, M.E., Stein, E.C., Porcelli, S., Betts, R.F., Connuck, D.M., Korones, D., Insel, R.A., Zahradnik, J.M., and Eby, R. (1989) Effect of oligosaccharide chain length, exposed terminal group, and hapten loading on the antibody response of human adults and infants to vaccines consisting of Haemophilus influenzae type b capsular antigen uniterminally coupled to the diphtheria protein CRMI97./. Immunol. 142, 2464-2468. [Pg.1043]

Haemophilus influenzae type b conjugate vaccine (Hib). (Minimum age 6 weeks)... [Pg.576]

Haemophilus influenzae type b (Hib) vaccines currently in use are conjugate products, consisting of either a polysaccharide or oligosaccharide of polyribosylribitol phosphate (PRP) covalently linked to a protein carrier. [Pg.583]

Haemophilus influenzae Type B Conjugate Vaccine Products ... [Pg.583]

Available killed vaccines include acellular pertussis, anthrax, botulism, cholera, diptheria, hepatitis A, hepatitis B, Haemophilus influenzae type b (Hib), influenza, Lyme disease, meningococcus, pertussis, plague, pneumococcus, polio, rabies, tetanus, typhoid, and typhoid VI. [Pg.361]

For the combination vaccine use the diphtheria-tetanus-acellular pertussis (DTPa), inactivated polio (IPV) and Haemophilus influenzae type b (Hib) (Infanrix-Polio+H i ) vaccine (GlaxoSmithKline, Rixensart, Belgium). [Pg.471]

Trollfors B. Cost-benefit analysis of general vaccination against haemophilus influenzae type b in Sweden. Scand J Infect Dis 1994 26 611-14. [Pg.701]

Comvax (combination vaccine, containing rHBsAg produced in S. cerevisiae, as one component) Merck Vaccination of infants against Haemophilus influenzae type B and hepatitis B... [Pg.442]

Prophylaxis against relapses of rheumatic fever (secondary prevention of rheumatic heart disease) is discussed in Section II of this chapter. In most developed countries, national vaccination programs with vaccines against diphteria and Haemophilus influenzae type b have virtually eliminated the complications of diphteria and acute epiglottitis. [Pg.539]

Each lyophilisate for one immunising dose of diphtheria, tetanus toxoids and pertussis with Haemophilus b conjugate vaccine contains Haemophilus influenzae type b polysaccharide conjugated to tetanus protein 10 meg, purified diphtheria toxoid 1 immunising dose, purified tetanus toxoid 1 immunising dose, Bordetella pertussis minimum of 4.1 lU. [Pg.438]

Kayhty, H., V. Karanko, H. Peltola, and P.H. Makela, Serum antibodies after vaccination with Haemophilus influenzae type b capsular polysaccharide and responses to reimmunization no evidence of immunologic tolerance or memory. Pediatrics, 1984. 74(5) 857-65. [Pg.324]

Vaccination against invasive disease caused by Haemophilus influenzae type b in infants and children 2 to 71 months... [Pg.577]

Big Chemical Encyclopedia

Chemical substances, components, reactions, process design ...